Wide Ranks

IGMS

IGM Biosciences, Inc.

10.43

Top Statistics
Market Cap 620 M Forward PE -4.74 Revenue Growth 1.40 %
Current Ratio 5.22 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.00 Enterprise / Revenue 153.28 Price To Sales Trailing12 Months 212.55
Profitability
Profit Margins 0.00 % Operating Margins -12478.10 %
Balance Sheet
Total Cash 218 M Total Cash Per Share 3.68 Total Debt 45 M
Total Debt To Equity 58.09 Current Ratio 5.22 Book Value Per Share 1.33
All Measures
Short Ratio 1197.00 % Message Board Id finmb_315179920 Shares Short Prior Month 3 M
Return On Equity -1.32 City Mountain View Uuid ec470288-8a03-31b9-966a-7fa24c6a00fa
Previous Close 9.46 First Trade Date Epoch Utc 1 B Book Value 1.33
Beta 0.1920 Total Debt 45 M Volume 190728
Price To Book 7.85 Fifty Two Week Low 5.58 Total Cash Per Share 3.68
Total Revenue 2 M Shares Short Previous Month Date 1 B Target Median Price 17.50
Max Age 86400 Recommendation Mean 2.20 Sand P52 Week Change 0.3133
Operating Margins -12478.10 % Target Mean Price 19.60 Net Income To Common -219843008
Short Percent Of Float 0.1869 Implied Shares Outstanding 59 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 246600 Average Volume10days 246600
Total Cash 218 M Next Fiscal Year End 1 B Revenue Per Share 0.0480
Held Percent Insiders 0.3504 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 9.46 Target Low Price 9.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 14.26 Open 9.45
Free Cashflow -100197128 State CA Dividend Yield 0.00 %
Return On Assets -0.3738 Time Zone Short Name EST Trailing Eps -3.61
Day Low 9.45 Address1 325 East Middlefield Road Shares Outstanding 34 M
Price Hint 2 Target High Price 48.00 Website https://igmbio.com
52 Week Change 0.5475 Average Volume 309212 Forward Eps -2.40
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 499.90 %
Is_sp_500 False Regular Market Day High 10.55 Profit Margins 0.00 %
Debt To Equity 58.09 Fifty Two Week High 22.50 Day High 10.55
Shares Short 2 M Regular Market Open 9.45 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 153.28 Revenue Growth 1.40 %
Shares Percent Shares Out 0.0478 Operating Cashflow -166184000 Currency USD
Time Zone Full Name America/New_York Market Cap 620 M Is_nasdaq_100 False
Zip 94043 Quote Type EQUITY Industry Biotechnology
Long Name IGM Biosciences, Inc. Regular Market Day Low 9.45 Held Percent Institutions 0.6399
Current Price 10.43 Enterprise To Ebitda -2.00 Financial Currency USD
Current Ratio 5.22 Industry Disp Biotechnology Number Of Analyst Opinions 10
Country United States Float Shares 11 M Two Hundred Day Average 10.95
Enterprise Value 447 M Price To Sales Trailing12 Months 212.55 Forward PE -4.74
Regular Market Volume 190728 Ebitda -223952992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.

It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.

IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.

The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.

IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.